Sacklers call opioid-related fraud claims ‘utterly meritless’

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Incyte advances its Opzelura eczema campaign with a ‘reimagine’ theme

Incyte’s newest campaign for Opzelura (ruxolitinib) encourages itchy patients to “Reimagine Relief” as it works to carve out a niche in the crowded eczema treatment

September 21, 2023

Ophthalmic biotech raises $16.5M; Pfizer’s AI collaboration bears fruit

Plus, news about Biodexa Pharmaceuticals: RevOpsis Therapeutics secures $16.5M seed round: The San Carlos, CA-based biotech will use the funds to complete IND-enabling studies for

April 27, 2024

Surfing the web too much? Study links problematic internet use to heightened ADHD symptoms

This meta-analysis reveals a significant association between problematic internet use (PIU) and symptoms of ADHD, particularly in adult males who are not clinically diagnosed. The

October 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.